Skip to main content
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
23.39
+0.35 (1.52%)
At close: Feb 27, 2026, 4:00 PM EST
22.93
-0.46 (-1.97%)
After-hours: Feb 27, 2026, 7:41 PM EST

Ultragenyx Pharmaceutical Revenue

In the year 2025, Ultragenyx Pharmaceutical had annual revenue of $673.00M with 20.18% growth. Ultragenyx Pharmaceutical had revenue of $207.28M in the quarter ending December 31, 2025, with 25.89% growth.

Revenue (ttm)
$673.00M
Revenue Growth
+20.18%
P/S Ratio
3.35
Revenue / Employee
$520,093
Employees
1,371
Market Cap
2.26B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025673.00M113.00M20.18%
Dec 31, 2024560.00M126.00M29.03%
Dec 31, 2023434.00M70.67M19.45%
Dec 31, 2022363.33M11.92M3.39%
Dec 31, 2021351.41M80.38M29.66%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Galapagos NV 1.31B
Telix Pharmaceuticals 803.79M
Zai Lab 460.16M
Adaptive Biotechnologies 276.98M
Stoke Therapeutics 205.63M
Mesoblast 65.38M
Ascentage Pharma Group International 54.52M
Immunome 9.68M
Revenue Rankings

RARE News

More News